Telaprevir in the Treatment of Acute Hepatitis C Virus Infection in HIV-Infected Men

Fierer, Daniel S.; Dieterich, Douglas T.; Mullen, Michael P.; Branch, Andrea D.; Uriel, Alison; Carriero, Damaris; Seggelen, Wouter O. van; Hijdra, Rosanne M.; Cassagnol, David G.; Akil, Bisher; Bailey, Juan; Bellman, Paul; Bowers, Daniel T.; Bungay, Krisczar; Burger, Susanne; Carpenter, W.T.; Chavez, Robert; Chow, Rita; Cohen, Robert M.; Dalton, Patrick; Dellosso, John; Demidont, Adrian; Dillon, Stephen M.; Donlon, Eileen; Farrow, Terry; Gardenier, Donald; Guadron, Rodolfo; Haber, Stephen; Higgins, Lawrence; Hitzeman, Lawrence; Hsu, Ricky; Huprikar, Shirish; Inada, Victor; Jacob, Sneha; Johnson, Livette; Johnston, Barbara; Kaminsky, Donald; Klein, Oscar; Kwong, Jeffrey; Lares-Guia, Jose; Leach, E. H.; Levine, Randy L.; Linetskaya, Irina; Литвинова, Л. С.; Malhotra, Amisha; Mandell, William; Markowitz, Martin; Mayer, Gal; Meraz, Eddie; Mortensen, Erik; Mh, Ng; Olivieri, Joseph; Paolino, Charles; Photangtham, Punyadech; Psevdos, George; Radix, Asa; Rapaport, Steven; Rodriguez-Caprio, Gabriela; Shay, William; Somasundaram, Nirupama; Sorra, Lembitu; Stivala, Alicia; Tran, Richie; Urbina, Antonio; Vail, Rona M.; Wallach, Francis; Wang, Wen; Weiss, Susan R.; Wiener, Melissa

doi:10.1093/cid/cit799

Cited by 66 publications

(48 citation statements)

References 39 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Till date, only one pilot study using Telaprevir with Peg-IFN/RBV for 19 patients with acute HCV/HIV coinfection has been reported, with 84% SVR rate. 164 Results of several studies using all-oral DAA-based regimens are awaited with interest 158 and are expected to change the paradigm for treatment of acute HCV infection.…”

Section: Antiviral Therapy For Ahcv Infectionmentioning

confidence: 99%

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Puri

Saraswat

Dhiman

et al. 2016

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

India contributes significantly to the global burden of HCV. While the nucleoside NS5B inhibitor sofosbuvir became available in the Indian market in March 2015, the other directly acting agents (DAAs), Ledipasvir and Daclatasvir, have only recently become available in the India. The introduction of these DAA in India at a relatively affordable price has led to great optimism about prospects of cure for these patients as not only will they provide higher efficacy, but combination DAAs as all-oral regimen will result in lower side effects than were seen with pegylated interferon alfa and ribavirin therapy. Availability of these newer DAAs has necessitated revision of INASL guidelines for the treatment of HCV published in 2015. Current considerations for the treatment of HCV in India include the poorer response of genotype 3, nonavailability of many of the DAAs recommended by other guidelines and the cost of therapy. The availability of combination DAA therapy has simplified therapy of HCV with decreased reliance of evaluation for monitoring viral kinetics or drug related side effects. ( J CLIN EXP HEPATOL 2016;6:119-145) T here have been revolutionary changes in the management of chronic hepatitis C (CH-C) over the last few years. Pegylated interferon alfa (Peg-IFNa) plus ribavirin (RBV) therapy, which till the recent past was the standard of care, has been eclipsed by the arrival of newer directly acting antiviral agents (DAAs). Not only do the DAAs have better efficacy, they are also associated with lower side effects, have better tolerability, a shorter duration of therapy, and have simpler administration.In the recent guidelines issued by the American Association for the study of Liver Diseases (AASLD), in collaboration with the Infectious Diseases Society of America 1 and the European Association for Study of the Liver z (EASL), 2 the role of Peg-IFNa/RBV therapy in the management of HCV has been relegated to second-line, backup status. These newer guidelines, however, cannot be implemented in India as many of the recommended drugs are yet to be marketed in India. Other considerations for the treatment of HCV in India are a predominance of

show abstract

Section: Antiviral Therapy For Ahcv Infectionmentioning

confidence: 99%

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Puri

Saraswat

Dhiman

et al. 2016

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

show abstract

“…Ten studies (83%) originated from Europe [6,38,39,40,41,42,43,44,45,46], mostly from the UK [38,40,41,45,46] and France [6,39,44]. Eight were prospective in study design [6,38,39,41,44,45,47,48]. Most studies [6,38,39,40,43,46,47,48] featured an ITT analysis.…”

Section: Resultsmentioning

confidence: 99%

“…Eight were prospective in study design [6,38,39,41,44,45,47,48]. Most studies [6,38,39,40,43,46,47,48] featured an ITT analysis. One study [46] included 3 patients who were each treated twice for 2 separate a-HCV infections.…”

Section: Resultsmentioning

confidence: 99%

Treatment of Acute Hepatitis C Infection with Pegylated Interferon and Ribavirin in Patients Coinfected with Human Immunodeficiency Virus: A Systematic Review and Meta-Analysis

Zhang

Nguyen²,

Yee³

et al. 2015

Intervirology

View full text Add to dashboard Cite

Background/Aims: Of the 35 million human immunodeficiency virus (HIV)-positive patients worldwide, 10-40% are coinfected with chronic hepatitis C virus (HCV). Compared to HCV-monoinfected patients, those coinfected experience decreased spontaneous HCV clearance, accelerated liver fibrosis, and a decreased response to anti-HCV therapy. We conducted a meta-analysis to estimate the efficacy of treating acute HCV in HIV-positive patients with peginterferon and ribavirin combination therapy. Methods: Two authors independently searched MEDLINE and EMBASE (2014) for English articles, and reviewed bibliographies and abstracts from major liver and HIV conferences (2011-2013). Original studies featuring at least 10 treatment-naive, HIV-positive adults infected with acute HCV and treated with peginterferon and ribavirin were included. Analyses were calculated using a random-effects model. Heterogeneity was assessed using the Cochrane Q test (p < 0.05) and the I² statistic (>50%). Results: From 12 studies (450 patients), the pooled sustained virological response (SVR) was 71.4% (95% CI 64.7-77.4; Q statistic = 22.20, p = 0.023, I² = 50.44). The rapid virological response (RVR; 7 studies, 196 patients) was 47.4% (95% CI 40.6-54.7), and the early virological response (EVR; 9 studies, 283 patients) was 82.8% (95% CI 67.0-92.0). The probability of an SVR was 93.1% (95% CI 84.9-97.0) in those who obtained an RVR (6 studies, 82 patients) and 85.9% (95% CI 78.7-91.0) if an EVR (7 studies, 168 patients) was reached. Conclusion: Peginterferon with ribavirin is an effective option for treating acute HCV in HIV-positive patients, especially if they achieve an RVR or an EVR.

show abstract

“…The other choice is the addition of protease inhibitor to peg-IFN + ribavirin combination. Data obtained through the New York acute hepatitis C Surveillance Network showed that a 12-week treatment course with a combination of peg-IFN + ribavirin + telaprevir achieved SVR in 84% of 19 human immunodeficiency virus (HIV)-infected men with acute genotype 1 HCV infection (23). SVR was also detected at the rate of 78% with triple combination treatment with boceprevir (BOC) in the similar patient population and SVR rate was reported to be 95% in the group who achieved rapid virologic response (24).…”

Section: Interferon-based Therapiesmentioning

confidence: 99%

Current Treatment Approach in Acute Hepatitis C Infection

Güner¹,

Kayaaslan²

2017

vhd

View full text Add to dashboard Cite

Telaprevir in the Treatment of Acute Hepatitis C Virus Infection in HIV-Infected Men

Cited by 66 publications

References 39 publications

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Treatment of Acute Hepatitis C Infection with Pegylated Interferon and Ribavirin in Patients Coinfected with Human Immunodeficiency Virus: A Systematic Review and Meta-Analysis

Current Treatment Approach in Acute Hepatitis C Infection

Contact Info

Product

Resources

About